Hospital Universitario Lucus Augusti — Clinical Trial Site

125 Registered trials

47 Currently recruiting

Organisation

Hospital Universitario Lucus Augusti

Location

Lugo, Spain

Identifier

ORG-100042119

Address

Rua Dr. Ulises Romero 1, 27003, Spain

Departments

034031: Oncología Médica
2502:Oncología
Alergología
Alergology
Allergy
Anestesia
Cardiologia
CARDIOLOGY
Cirugía general
Departamento Urologia
Department of Urology
Digestivo
Enfermedades Infecciosas
Hematología
Hematology
Hematology and Hemotherapy
HU Lucus Augusti
infectious diseases
Lipids Unit
Medica Oncology
medical oncologist
Medical Oncology
Medical Oncology Department
N/A
Neurology Service
Oncologia
Oncología Médica
Oncology
Oncology Department
Oncology Service
Pneumology
Pneumology Service
Radiation Oncology
Respiratory Medicine
Reumatología
Servicio de digestivo
Servicio de Oncologia
Servicio de Oncologia Medica
Surgery
UCG Enfermedades Infecciosas, Microbiología y Medicina preventiva
Urology

Clinical trials at this site (125)

Search interface

HARMONi-3 Not authorised

2023-504989-37-00 Metastatic Squamous Non-small Cell Lung Cancer 5
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inh… Not authorised

2023-505311-20-00 Metastatic Non-Small Cell Lung Cancer 5
A trial to learn how safe durvalumab with chemotherapy is and how well it works in adults with muscle-invasive bladder cancer Pending

2024-519246-75-01 Patients With Muscle-Invasive Bladder Cancer 4
Moonlanding: A phase 2 study of pembrolizumab plus belzutifan, with or without lenvatinib, given before the main treatment for localized kid… Pending

2024-519673-18-00 Patients with localized renal cell carcinoma 4
In vivo biological standardization of Lepidoglyphus destructor allergen extract Pending

2025-520753-37-00 Allergies 4
CLINICAL TRIAL WITH APROTININ IN THE ACUTE RESPIRATORY DISTRESS SYNDROME TREATMENT Pending

2025-520826-39-00 ACUTE RESPIRATORY DISTRESS SYNDROME 5
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending

2025-522475-28-00 Pulmonary Hypertension (PH) with Heart Failure with pre 5
Clinical trial to assess the efficacy and safety of a vaccine for dust mite and Lepidoglyphus destructor allergy. Pending

2025-522771-28-00 Aetiological treatment of moderate-to-severe allergic r 5
A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia… Pending

2025-523238-17-00 Acute myeloid leukemia 4
Allergen extract of Lepidoglyphus destructor. Study of the sensitivity and specificity of the diagnostic preparation in prick tests Pending

2025-523426-40-00 Allergy to Lepidoglyphus destructor 5
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate r… Pending

2025-524005-32-00 Rheumatoid arthritis 4
A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures Recruiting

2025-524038-24-00 Focal Epilepsy 5 2026-05-22
A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC Recruiting

2025-522867-13-00 Non Small Cell Lung Cancer 4 2026-04-27
Testing HLX43 in Advanced Lung Cancer (Non-Small Cell): A Global Safety and Effectiveness Study Recruiting

2025-523803-31-00 Advanced non-small cell lung cancer (NSCLC) 4 2026-04-16
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA) Recruiting

2024-512436-29-00 CARDIOVASCULAR DISEASES 11 2026-03-27
Phase II study on the safety and feasibility of stool transplants in limited non-small cell lung cancer patients, using donors who responded… Recruiting

2025-521251-24-00 Non-Small cell lung cancer (NSCLC) 4 2025-12-01
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici… Recruiting

2024-516792-32-01 Metastatic non-squamous non-small cell lung cancer 4 2025-07-18
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a… Recruiting

2023-505172-29-00 Resectable Non-small Cell Lung Cancer 4 2025-04-24
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized… Recruiting

2023-508441-41-00 Bacteriemia producida por P. aeruginosa. 6 2024-07-08
AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting

2023-504214-30-00 Metastatic Castration-Sensitive Prostate Cancer (mCSPC) 5 2024-06-27
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting

2023-506784-33-00 RET fusion-Positive NSCLC 5 2021-01-19